Ayla A. Kessler
Experienced in Malignant Mixed Mullerian Tumor

Dr. Ayla A. Kessler

Oncology | Hematology | Hematology Oncology
Ashe Memorial Hospital Inc
200 Hospital Ave, 
Jefferson, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Malignant Mixed Mullerian Tumor
Ashe Memorial Hospital Inc
200 Hospital Ave, 
Jefferson, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ayla Kessler is an Oncologist and a Hematologist in Jefferson, North Carolina. Dr. Kessler is rated as an Experienced provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Angiosarcoma, Breast Cancer, Inflammatory Breast Cancer, and Familial Colorectal Cancer. Dr. Kessler is currently accepting new patients.

Her clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Watauga Medical Center
Ashe Memorial Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

ASHE MEMORIAL HOSPITAL INC
200 Hospital Ave, Jefferson, NC 28640

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Drug
Study Drug: Carvedilol
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials
Similar Doctors
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Paul R. Kramer
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Paul R. Kramer
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
6 Sheridan Sq, Suite 100, 
Kingsport, TN 
 (61.5 miles away)
423-245-1040
Languages Spoken:
English
See accepted insurances

Paul Kramer is a Gynecologic Oncologist and an Oncologist in Kingsport, Tennessee. Dr. Kramer is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Ovarian Carcinosarcoma, and Hernia Surgery.

Advanced in Malignant Mixed Mullerian Tumor
Dr. Asheesh Shipstone
Hematology Oncology | Hematology | Oncology
Advanced in Malignant Mixed Mullerian Tumor
Dr. Asheesh Shipstone
Hematology Oncology | Hematology | Oncology

Wps Providers Inc

2202 N John B Dennis Hwy, Suite 110, 
Kingsport, TN 
 (59.2 miles away)
423-578-8400
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Asheesh Shipstone is a Hematologist Oncology specialist and a Hematologist in Kingsport, Tennessee. Dr. Shipstone is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Adult Immune Thrombocytopenia, Colorectal Cancer, Hemangioma Thrombocytopenia Syndrome, and Thrombocytopenia. Dr. Shipstone is currently accepting new patients.

Advanced in Malignant Mixed Mullerian Tumor
Dr. Dennis C. Desimone
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Advanced in Malignant Mixed Mullerian Tumor
Dr. Dennis C. Desimone
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

Wps Providers Inc

2202 N John B Dennis Hwy, Suite 110, 
Kingsport, TN 
 (59.2 miles away)
423-578-8400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dennis Desimone is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Kingsport, Tennessee. Dr. Desimone is rated as an Advanced provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Neuroendocrine Carcinoma of the Cervix, Cervical Cancer, Malignant Mixed Mullerian Tumor, Endometrial Cancer, and Hernia Surgery. Dr. Desimone is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kessler's expertise for a condition
ConditionClose
      View All 13 Advanced Conditions
      View All 82 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile